Intervacc AB (SE:IVACC)
:IVACC
Want to see SE:IVACC full AI Analyst Report?
IVACC Stock Chart & Stats
kr0.92
-kr0.06(-5.24%)
At close: 4:00 PM EST
kr0.92
-kr0.06(-5.24%)
Day’s Range― - ―
52-Week Rangekr0.57 - kr1.46
Previous CloseN/A
Volume791.15K
Average Volume (3M)373.34K
Market Cap
kr408.29M
Enterprise Valuekr257.57M
Total Cash (Recent Filing)kr145.63M
Total Debt (Recent Filing)kr357.00K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 20, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding340,813,200
10 Day Avg. Volume453,808
30 Day Avg. Volume373,337
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)kr44.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BufferA low-debt, equity-rich balance sheet provides durable financial flexibility: it lengthens runway for R&D and commercialization, reduces insolvency risk during product rollouts, and supports non-dilutive partner deals or targeted financing over the coming months.
Commercial Product With Defined Go-to-marketOwning an approved commercial vaccine (Strangvac) gives Intervacc a persistent revenue base and commercialization pathway. Established distribution partnerships and product-market fit in equine strangles create a defensible niche and a platform for incremental geographic expansion.
Improving Free Cash Flow TrendA ~48% improvement in free cash flow versus the prior period indicates operational progress and tighter cost control. If sustained, this trend materially reduces external funding needs and improves sustainability of operations over the next several quarters.
Bears Say
Large Persistent Cash BurnVery large negative operating and free cash flows erode runway and force recurrent capital raises or partner financing. Persistent burn constrains strategic optionality, can dilute shareholders, and makes long-term investment in commercialization or pipeline expansion more difficult.
Negative Gross Profit And Extreme Operating LossesNegative gross profit means the business currently fails to cover direct product costs, implying problematic unit economics or pricing. Extremely wide operating losses indicate structural unprofitability that must be fixed before sustainable scale or durable margins can be achieved.
Concentration On Single Product And Partner TermsHeavy reliance on one commercial vaccine and third‑party distribution concentrates execution and market risks. Adoption, partner terms, or regulatory setbacks in key markets would have outsized impact on revenue, limiting diversification and increasing long-term volatility of cash flows.
Intervacc AB News
IVACC FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was kr0.57 and its highest was kr1.46 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is kr408.29M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 90 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -kr0.06 earnings per share for the quarter, the consensus estimate of -kr0.06 by kr0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is -0.05.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -kr0.06 in its last earnings report, expectations of -kr0.06. Following the earnings report the stock price went down -14.82%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in SE:IVACC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―